BMC Medicine

official impact factor 5.75
Search for
Advanced search
BMC Medicine
Tools
Share this article
Open Access Email this article to a friend

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study

Dimitrios Bafaloukos, Helena Linardou*, Gerasimos Aravantinos, Christos Papadimitriou, Aristotelis Bamias, George Fountzilas, Haralabos P Kalofonos, Paris Kosmidis, Eleni Timotheadou, Thomas Makatsoris, Epaminondas Samantas, Evangelos Briasoulis, Christos Christodoulou, Pavlos Papakostas, Dimitrios Pectasides and Athanasios M Dimopoulos

BMC Medicine 2010, 8:3 doi:10.1186/1741-7015-8-3

Fields marked * are required


Multiple email addresses should be separated with commas or semicolons.